When to Give IV Iron and How to Calculate the Right Dose
Intravenous iron should be administered as first-line treatment when hemoglobin is below 10 g/dL, in patients with active inflammatory disease, with previous oral iron intolerance, or when erythropoiesis-stimulating agents are needed 1.
Indications for IV Iron
Primary indications include:
- Hemoglobin < 10 g/dL - IV iron is superior to oral iron and provides faster response 1
- Clinically active inflammatory bowel disease - oral iron fails due to absorption blocks 1
- Previous intolerance to oral iron - gastrointestinal side effects occur in up to 60% of patients 2
- Chronic kidney disease patients on hemodialysis - oral iron cannot maintain adequate stores 3
- Heart failure with reduced ejection fraction (LVEF ≤40%) with iron deficiency - improves functional capacity and reduces hospitalizations 2
- Need for ESA therapy - iron adequacy optimizes erythropoietin response 1
Iron deficiency is diagnosed when:
- Ferritin < 100 μg/L, OR
- Ferritin 100-299 μg/L with transferrin saturation (TSAT) < 20% 2
Dose Calculation Methods
Simplified Weight and Hemoglobin-Based Dosing (Preferred)
This simple scheme is more effective and better tolerated than Ganzoni formula 1. Use the following table:
| Hemoglobin (g/dL) | Body Weight <70 kg | Body Weight ≥70 kg |
|---|---|---|
| 10-12 (women) or 10-13 (men) | 1000 mg | 1500 mg |
| 7-10 | 1500 mg | 2000 mg |
Important caveats:
- For hemoglobin < 7.0 g/dL, add an additional 500 mg to the calculated dose 1
- For iron deficiency without anemia, consider a minimum of 500-1000 mg 1
Heart Failure Dosing
For chronic heart failure patients, use this specific algorithm 2:
| Hemoglobin | Body Weight <35 kg | 35 to <70 kg | ≥70 kg |
|---|---|---|---|
| <10 g/dL (<6.2 mmol/L) | 500 mg | 1500 mg | 2000 mg |
| 10 to <14 g/dL (6.2 to <8.7 mmol/L) | 500 mg | 1000 mg | 1500 mg |
| 14 to 15 g/dL (8.7 to 9.3 mmol/L) | 500 mg | 500 mg | 500 mg |
Do not administer IV iron if hemoglobin >15 g/dL 2.
Chronic Kidney Disease Dosing
For hemodialysis patients, provide 250-1000 mg within 12 weeks as maintenance 3. Initial repletion typically requires 1000 mg total, administered as:
- 100 mg per dose for in-center hemodialysis (to minimize arthralgias/myalgias) 3
- Given weekly for 10 weeks 3
For non-dialysis CKD patients, 500-1000 mg can be given as a single infusion over 1 hour 3.
Pregnancy Dosing
Timing is critical - the earlier IV iron is administered, the greater the hemoglobin response 4, 5:
- Optimal timing: 6-12 weeks before delivery shows the greatest benefit (Δ2.75-3.1 g/dL increase) 5
- Minimum effective timing: At least 2 weeks before delivery 5
- Dose: ≥800 mg total dose shows superior outcomes 4
- Consider adjusted body weight for dosing calculations: IBW + [0.4 × (TBW - IBW)] 6
Formulation Selection and Administration
Modern high-dose formulations allow single-administration repletion 7:
Ferric Carboxymaltose (FCM)
- Single doses: 500-1000 mg (up to 20 mg/kg, maximum 1000 mg/week) 1
- Administration: Undiluted slow bolus over 15 minutes, or diluted in 100 mL saline over 20-30 minutes 2, 7
- Caution: Associated with hypophosphatemia; avoid for repeat infusions 7
Ferric Derisomaltose (FDI)
- Dose: Up to 20 mg/kg, not exceeding 1500 mg 7
- Only formulation with FDA-approved total dose infusion label 7
- Shown to reduce cardiovascular death in heart failure patients 7
Iron Sucrose
- Limited to 200-300 mg per treatment episode 1
- Requires multiple administrations for total repletion 1
Iron Dextran
- Requires test dose due to anaphylaxis risk 1
- If used, prefer low-molecular-weight formulation (INFeD) over high-molecular-weight (Dexferrum) 8
Monitoring and Reassessment
Do not check iron parameters within 4 weeks of total dose infusion - circulating iron interferes with assays 7.
Appropriate monitoring timeline:
- Hemoglobin: Should increase 1-2 g/dL within 4-8 weeks 1, 7
- Iron parameters (ferritin, TSAT): Check at 4-8 weeks post-infusion 7
- Heart failure patients: Reassess at 3 months, then 1-2 times yearly 2
- CKD patients: Monitor every 3 months during maintenance 3
Target parameters:
- Ferritin ≥50 ng/mL (in absence of inflammation) 7
- TSAT ≥20% 3
- Upper safety limits: Ferritin <800 μg/L, TSAT <50% 1
Common Pitfalls to Avoid
- Do not use Ganzoni formula - it underestimates requirements and is prone to error 1
- Do not rely on MCV, MCH, or serum iron alone - these are unreliable markers 2
- Do not give oral iron when IV is indicated - oral iron is ineffective in inflammatory states and poorly tolerated 2
- Do not administer during active bacteremia - stop treatment until infection resolves 2
- Do not underdose - inadequate dosing prolongs anemia and increases morbidity 3
- Observe patients for 30 minutes post-infusion for hypersensitivity reactions 2